These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39153203)

  • 21. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
    Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
    Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.
    Eroglu Z; Chen YA; Smalley I; Li J; Markowitz JK; Brohl AS; Tetteh L; Taylor H; Sondak VK; Khushalani NI; Smalley KSM
    Cancer; 2024 Jan; 130(2):232-243. PubMed ID: 37776537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
    Mooradian MJ; Cleary JM; Giobbie-Hurder A; Darville LNF; Parikh A; Buchbinder EI; Cohen JV; Lawrence DP; Shapiro GI; Keer H; Chen HX; Ivy SP; Smalley KSM; Koomen JM; Sullivan RJ
    Cancer; 2023 Jun; 129(12):1904-1918. PubMed ID: 37042037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.
    Serwetnyk MA; Blagg BSJ
    Acta Pharm Sin B; 2021 Jun; 11(6):1446-1468. PubMed ID: 34221862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors.
    Zhao J; Zhao H; Hall JA; Brown D; Brandes E; Bazzill J; Grogan PT; Subramanian C; Vielhauer G; Cohen MS; Blagg BS
    Medchemcomm; 2014 Sep; 5(9):1317-1323. PubMed ID: 25328661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.
    Garg G; Zhao H; Blagg BS
    ACS Med Chem Lett; 2015 Feb; 6(2):204-9. PubMed ID: 25699150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of HSP90 in melanoma.
    Mielczarek-Lewandowska A; Hartman ML; Czyz M
    Apoptosis; 2020 Feb; 25(1-2):12-28. PubMed ID: 31659567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances toward the development of Hsp90 C-terminal inhibitors.
    Amatya E; Blagg BSJ
    Bioorg Med Chem Lett; 2023 Jan; 80():129111. PubMed ID: 36549397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.
    Yun BG; Huang W; Leach N; Hartson SD; Matts RL
    Biochemistry; 2004 Jun; 43(25):8217-29. PubMed ID: 15209518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a new scaffold for hsp90 C-terminal inhibition.
    Zhao H; Moroni E; Colombo G; Blagg BS
    ACS Med Chem Lett; 2014 Jan; 5(1):84-8. PubMed ID: 24900777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
    Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
    Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.
    Allan RK; Mok D; Ward BK; Ratajczak T
    J Biol Chem; 2006 Mar; 281(11):7161-71. PubMed ID: 16421106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novobiocin Analogs as Potential Anticancer Agents.
    Dlugosz A; Janecka A
    Mini Rev Med Chem; 2017; 17(9):728-733. PubMed ID: 28019639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined BRAF and HSP90 Inhibition in Patients with Unresectable
    Eroglu Z; Chen YA; Gibney GT; Weber JS; Kudchadkar RR; Khushalani NI; Markowitz J; Brohl AS; Tetteh LF; Ramadan H; Arnone G; Li J; Zhao X; Sharma R; Darville LNF; Fang B; Smalley I; Messina JL; Koomen JM; Sondak VK; Smalley KSM
    Clin Cancer Res; 2018 Nov; 24(22):5516-5524. PubMed ID: 29674508
    [No Abstract]   [Full Text] [Related]  

  • 35. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
    Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
    Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
    Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
    Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
    Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
    BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
    Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
    Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.